Results 171 to 180 of about 4,076 (204)

Targeting hippocampal amyloidogenesis with SV2A protein modulator levetiracetam

Biochemical Pharmacology, 2022
Cerebral amyloid β (Aβ) proteostasis is compromised under neuronal overexcitation, long-term neuroinflammation and brain aging. Using the animal model of LPS-induced neuroinflammation we demonstrated that treatment with levetiracetam, a specific modulator of synaptic vesicle glycoprotein SV2A, rescues abnormal synaptic vesicle (SV) fusion and ...
Ludmila A, Kasatkina, Vitaliy P, Gumenyuk, Olha O, Lisakovska, Irene O, Trikash   +3 more
openaire   +2 more sources

Levetiracetam: the first SV2A ligand for the treatment of epilepsy

Expert Opinion on Drug Discovery, 2007
Levetiracetam is a multiple action drug that primarily acts through an interaction with the synaptic vesicle protein 2A. Levetiracetam is the first drug of its kind to be approved for the treatment of epilepsy and is now the most prescribed among the newer antiepileptic drugs.
Henrik, Klitgaard, Peter, Verdru
openaire   +2 more sources

In Vivo Measurement of Widespread Synaptic Loss in Alzheimer's Disease With SV2A PET

Alzheimer's and Dementia, 2020
AbstractIntroductionSynaptic loss is a robust and consistent pathology in Alzheimer's disease (AD) and the major structural correlate of cognitive impairment. Positron emission tomography (PET) imaging of synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising biomarker of synaptic density.MethodsWe measured SV2A binding in 34 participants ...
Ryan S O'Dell, Nabeel Nabulsi, Takuya Toyonaga   +2 more
exaly   +3 more sources

SV2A and SV2C contain a unique synaptotagmin-binding site

Molecular and Cellular Neuroscience, 2005
SV2 (Synaptic Vesicle Protein 2) is expressed in neurons and endocrine cells where it is required for normal calcium-evoked neurosecretion. In mammals, there are three SV2 genes, denoted SV2A, B and C. SV2A interacts with synaptotagmin, the prime candidate for the calcium sensor in exocytosis.
Amanda E, Schivell, Sumiko, Mochida, Patricia, Kensel-Hammes, Kenneth L, Custer, Sandra M, Bajjalieh   +4 more
openaire   +2 more sources

Visualization of SV2A conformations in situ by the use of Protein Tomography

Biochemical and Biophysical Research Communications, 2008
The synaptic vesicle protein 2A (SV2A), the brain-binding site of the anti-epileptic drug levetiracetam (LEV), has been characterized by Protein Tomography. We identified two major conformations of SV2A in mouse brain tissue: first, a compact, funnel-structure with a pore-like opening towards the cytoplasm; second, a more open, V-shaped structure with ...
Berkley A, Lynch, Alain, Matagne, Annika, Brännström, Anne, von Euler, Magnus, Jansson, Elenor, Hauzenberger, J Arvid, Söderhäll   +6 more
openaire   +2 more sources

Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model

Neurology, 2007
To assess the activity of brivaracetam, a novel SV2A ligand, in the photosensitivity model as a proof-of-principle of efficacy in patients with epilepsy.A subject-blind placebo-controlled study in patients with photosensitive epilepsy was performed to investigate the effect of single-dose brivaracetam (10, 20, 40, or 80 mg) on photosensitive responses.
D G A, Kasteleijn-Nolst Trenité, P, Genton, D, Parain, P, Masnou, B J, Steinhoff, T, Jacobs, E, Pigeolet, A, Stockis, E, Hirsch   +8 more
openaire   +2 more sources

Behavioural Phenotyping Reveals Anxiety-Like Features of SV2A Deficient Mice

Behavioural Brain Research, 2009
Synaptic vesicle protein 2A (SV2A) is involved in neurotransmitter release and has been identified as the binding site for levetiracetam (Keppra), a novel antiepileptic drug. Homozygous SV2A (-/-) mice are not viable beyond a few weeks. In contrast, heterozygous SV2A (+/-) mice have a normal lifespan. We performed a behavioural phenotyping on SV2A (+/-)
Yves Lamberty, Karine Leclercq
exaly   +3 more sources

No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy [PDF]

Epilepsy Research, 2009
Levetiracetam (LEV), a newer antiepileptic drug (AED) useful for several epilepsy syndromes, binds to SV2A. Identifying genetic variants that influence response to LEV may allow more tailored use of LEV. Obvious candidate genes are SV2A, SV2B and SV2C, which encode the only known binding site, synaptic vesicle protein 2 (SV2), with LEV binding to the ...
Lynch, JM, Tate, SK, Kinirons, P, Weale, ME, Cavalleri, GL, Depondt, C, Murphy, K, O-Rourke, D, Doherty, CP, Shianna, KV, Wood, NW, Sander, JW, Dalanty, N, Goldstein, DB, Sisodiya, SM   +14 more
openaire   +3 more sources

Use of SV2A antagonist for the epilepsy treatment

2018
Isan Journal of Pharmaceutical Sciences, 14, 3, 16 ...
openaire   +1 more source

Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis

CNS & Neurological Disorders - Drug Targets, 2017
Dysfunction of synaptic neurotransmitter release is closely involved in the pathogenesis of various central nervous system diseases. Synaptic vesicle glycoprotein 2A (SV2A) is a membrane protein specifically expressed in synaptic vesicles and it modulates action potential-dependent neurotransmitter release in the brain.
Yukihiro, Ohno, Kentaro, Tokudome
openaire   +2 more sources